A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
he purpose of the study is to evaluate the efficacy, safety, and tolerability BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants with relapsed/refractory non-Hodgkin follicular lymphoma.
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
DRUG: Zanubrutinib|DRUG: Obinutuzumab
Overall Response Rate (ORR) by Independent Review Committee (IRC) Assessment, ORR is defined as the percentage of participants who achieve either complete response (CR) or partial response (PR) as best overall response, as assessed by the IRC using Lugano Classification for Non-Hodgkin Lymphoma, Through primary analysis data cut-off date of 08OCT2021 (up to approximately 3 years and 11 months)
Overall Response Rate (ORR) as Assessed by the Investigator, Up to approximately 7 years|Duration of Response (DOR), Up to approximately 7 years|Progression Free Survival (PFS), Up to approximately 7 years|Overall Survival (OS), Up to approximately 7 years|Complete Response Rate, Up to approximately 7 years|Complete Metabolic Response Rate, Up to approximately 7 years|Time to Response (TTR), Up to approximately 7 years|Health-Related Quality of Life (HRQOL) as Assessed by The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), Up to approximately 7 years|Health-Related Quality of Life (HRQOL) as Assessed by The 5-level EQ-5D Version (EQ-5D-5L), Up to approximately 7 years|Occurrence and Severity of Treatment-emergent Adverse Events (TEAEs), Safety and Tolerability, Up to approximately 7 years|Apparent Clearance (CL/F) of Zanubrutinib, Day 1 Cycle 1 and Day 2 Cycle 2: Predose|Area Under the Curve From 0 to 12 Hours Post Dose (AUC0-12), Day 1 Cycle 1 and Day 2 Cycle 2: Pre-dose
he purpose of the study is to evaluate the efficacy, safety, and tolerability BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants with relapsed/refractory non-Hodgkin follicular lymphoma.